Thus, the critical role of eEF-2K in upholding the activity and function of CTLs warrants further investigation to assess whether therapeutic augmentation of this kinase can be exploited as a novel approach to reinforcing CAR-T therapy against cancer. This evidence concerns the gene EEF2K and cancer.